BeiGene announces expansion of coverage on China’s NRDL

BeiGene announced that the National Reimbursement Drug List, NRDL, released by China’s National Healthcare Security Administration, NHSA, has been updated to include four new indications for its PD-1 inhibitor tislelizumab. KYPROLIS, a proteosome inhibitor licensed-in from Amgen, is included for the first time and XGEVA, a RANKL inhibitor and another Amgen asset, successfully renewed this year. The updated NRDL will officially take effect on March 1, 2023. "The expanded coverage of tislelizumab, new inclusion of KYPROLIS, as well as the renewal of XGEVA on the latest NRDL will allow more patients in China to have access to these high-quality medicines at affordable prices," said Xiaobin Wu, Ph.D., President, Chief Operating Officer, and General Manager of China, at BeiGene. "After several years of reform, the NHSA has established a basic medical insurance system with universal coverage. Through the annual updates of the NRDL, it made a leap forward in broadening access to innovative oncology medicines across China. At BeiGene, we share this same vision and endeavor to advance global health by making innovative medicines more accessible and affordable to patients in China and globally."